Mablink Bioscience is a biopharmaceutical company developing antibody-drug conjugates (ADC). It develops a propriety hydrophilic linker platform and approach for developing drugs, thereby developing a hydrophilic platform for next-generation ADCs. The company offers PSARlink, an innovative and hydrophilic drug-linker technology that brings improved pharmacological properties to antibody-drug conjugates.